Abstract
The objective of this study is to assess scope and role of drug therapies in cardiology/vascular diseases in AOTM works. AOTM is one of a light touch HTA Agencies around the world with respect to drugs evaluation before desion-taking on reimbursement and pricing. AOTM stands for quality assurance of HTA reports developed by industry applying for inclusion of drugs to BBP (basic benefit package). It deals also with appraisal of submitted evidence. AOTM does not develop HTA reports from the scratch with respect to drugs. Therefore no priority setting process is needed and no bias in selection of topics for assessment should be in place. Among recommendations of AOTM published until the end of 2011 we analyzed all related to cardiovascular drugs. Among 400 AOTM decisions verified only 31 (8%) were related to cardiovascular drugs. Recommendation regarding non–drug technologies were issued to 47 (12%) of 400 technologies. 58 (15%) applied to drugs used in the treatment of nervous disorders, 34 (9%) metabolic disorders, 21 (5%) genito-urinary system. The largest number (142/36% of 400) of analyzed submission was connected with antineoplastic and immunomodulating agents; 105 (74%) of them regarding oncology treatment. Fifteen percent of verified docummentations applied to other, single indications. The influence of cardiovascular drugs for AOTM recommendations were not significant and no bias with respect to special focus on cardiovascular drugs has been observed in comparision to focus on other medicines. Most of commissions prepared by AOTM were related to antineoplastic (cancer chemotherapy) treatment representing normal trends in research and development in medicine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
